DEGS1 variant causes neurological disorder.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
11 2019
Historique:
received: 03 02 2019
accepted: 14 05 2019
revised: 04 05 2019
pubmed: 13 6 2019
medline: 21 7 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

Sphingolipidoses are monogenic lipid storage diseases caused by variants in enzymes of lipid synthesis and metabolism. We describe an autosomal recessive complex neurological disorder affecting consanguineous kindred. All four affected individuals, born at term following normal pregnancies, had mild to severe intellectual disability, spastic quadriplegia, scoliosis and epilepsy in most, with no dysmorphic features. Brain MRI findings were suggestive of leukodystrophy, with abnormal hyperintense signal in the periventricular perioccipital region and thinning of the body of corpus callosum. Notably, all affected individuals were asymptomatic at early infancy and developed normally until the age of 8-18 months, when deterioration ensued. Homozygosity mapping identified a single 8.7 Mb disease-associated locus on chromosome 1q41-1q42.13 between rs1511695 and rs537250 (two-point LOD score 2.1). Whole exome sequencing, validated through Sanger sequencing, identified within this locus a single disease-associated homozygous variant in DEGS1, encoding C4-dihydroceramide desaturase, an enzyme of the ceramide synthesis pathway. The missense variant, segregating within the family as expected for recessive heredity, affects an evolutionary-conserved amino acid of all isoforms of DEGS1 (c.656A>G, c.764A>G; p.(N219S), p.(N255S)) and was not found in a homozygous state in ExAC and gnomAD databases or in 300 ethnically matched individuals. Lipidomcs analysis of whole blood of affected individuals demonstrated augmented levels of dihydroceramides, dihydrosphingosine, dihydrosphingosine-1-phosphate and dihydrosphingomyelins with reduced levels of ceramide, sphingosine, sphingosine-1-phosphate and monohexosylceramides, as expected in malfunction of C4-dihydroceramide desaturase. Thus, we describe a sphingolipidosis causing a severe regressive neurological disease.

Identifiants

pubmed: 31186544
doi: 10.1038/s41431-019-0444-z
pii: 10.1038/s41431-019-0444-z
pmc: PMC6871177
doi:

Substances chimiques

Ceramides 0
Cerebrosides 0
Lysophospholipids 0
ceramide monohexoside 0
dihydroceramide 0
dihydrosphingosine 1-phosphate 19794-97-9
sphingosine 1-phosphate 26993-30-6
Fatty Acid Desaturases EC 1.14.19.-
DEGS1 protein, human EC 1.14.99.-
Sphingosine NGZ37HRE42
safingol OWA98U788S

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1668-1676

Subventions

Organisme : NCI NIH HHS
ID : P01 CA097132
Pays : United States

Références

Brain. 2018 Apr 1;141(4):961-970
pubmed: 29522154
Mol Genet Metab. 2015 Apr;114(4):501-515
pubmed: 25655951
J Biol Chem. 2015 Jun 19;290(25):15371-9
pubmed: 25947377
Cell Metab. 2007 Mar;5(3):167-79
pubmed: 17339025
Biochim Biophys Acta. 2013 Nov;1833(11):2511-8
pubmed: 23611790
J Biol Chem. 2018 Jun 22;293(25):9922-9923
pubmed: 29934368
Open Biol. 2017 May;7(5):
pubmed: 28566300
J Biol Chem. 2007 Jun 8;282(23):16718-28
pubmed: 17283068
J Neurochem. 2019 Mar;148(5):600-611
pubmed: 29959861
J Clin Invest. 2019 Mar 1;129(3):1229-1239
pubmed: 30620338
Cell Mol Life Sci. 2019 Mar;76(6):1107-1134
pubmed: 30523364
J Clin Invest. 2019 Mar 1;129(3):1240-1256
pubmed: 30620337
PLoS Genet. 2016 Mar 23;12(3):e1005919
pubmed: 27008544
FASEB J. 2010 Sep;24(9):3341-50
pubmed: 20430792
Biochimie. 2016 Nov;130:146-151
pubmed: 27157270
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
FASEB J. 2018 Jun;32(6):3058-3069
pubmed: 29401619
Prog Lipid Res. 2012 Apr;51(2):82-94
pubmed: 22200621

Auteurs

Vadim Dolgin (V)

The Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.

Rachel Straussberg (R)

Neurogenetics Clinic, Neurology Unit, Schneider Children Medical Center, Petah Tikvah, Israel.

Ruijuan Xu (R)

Department of Medicine and Stony Brook Cancer Center, The State University of New York at Stony Brook, Stony Brook, New York, 11794, USA.

Izolda Mileva (I)

Department of Medicine and Stony Brook Cancer Center, The State University of New York at Stony Brook, Stony Brook, New York, 11794, USA.

Yuval Yogev (Y)

The Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.

Raed Khoury (R)

Department of Dermatology, Soroka University Medical Center, Beer-Sheva, 84101, Israel.

Osnat Konen (O)

Radiology Department, Schneider Children Medical Center, Petah Tikvah, Israel.

Yael Barhum (Y)

Transplantation Immunology Laboratory, Rabin Medical Center, Petah Tikvah, Israel.

Alex Zvulunov (A)

Department of Dermatology, Soroka University Medical Center, Beer-Sheva, 84101, Israel.

Cungui Mao (C)

Department of Medicine and Stony Brook Cancer Center, The State University of New York at Stony Brook, Stony Brook, New York, 11794, USA.

Ohad S Birk (OS)

The Morris Kahn Laboratory of Human Genetics, National Institute for Biotechnology in the Negev and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel. obirk@bgu.ac.il.
Genetics Institute, Soroka University Medical Center, Beer-Sheva, 84101, Israel. obirk@bgu.ac.il.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH